For the Inventor, By the Inventor

Enter assignee name

Boston, MA, United States of America

Alexion Pharmaceuticals, Inc.

USPTO Granted Patents = 199

% Expired Patents = 17.1

CIPO Patents = 19

EPO Patents = 76

Trademarks = 17

Forward Citations = 1,682

Loading Chart...

Loading Chart...

243 inventors (with patents filed for the assignee):

Russell P Rother (36 out of 38 patents)

Katherine S Bowdish (27 out of 27 patents)

Douglas L Sheridan (25 out of 25 patents)

4. Paul P Tamburini (22 out of 29 patents)

5. Yi Wang (21 out of 21 patents)

6. Stephen P Squinto (12 out of 16 patents)

7. John R McWhirter (12 out of 75 patents)

8. Anthony Quinn (11 out of 14 patents)

9. Anke Kretz-Rommel (11 out of 14 patents)

10. Scott A Rollins (11 out of 18 patents)

11. Leonard Bell (10 out of 14 patents)

12. Bruce A Andrien, Jr (10 out of 27 patents)

13. Shana Frederickson (10 out of 10 patents)

14. Yuchun Zhang (9 out of 9 patents)

15. Toshiaki Maruyama (9 out of 10 patents)

Core Competencies:

Anti-C5 Antibodies

Alkaline Phosphatase

Cerdulatinib

Complement Disorders

Atypical Hemolytic Uremic Syndrome

Monovalent Antibodies

Lysosomal Storage Diseases

Protein Kinase Inhibitors

Recombinant Therapeutics

B-Cell Malignancies

Tumor Response Biomarkers

Antidotes for Factor Xa

199 patents: Sort by Forward Citations

1. 12617846 - SUBCUTANEOUS (SC) ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF COMPLEMENT-ASSOCIATED CONDITIONS (2026-05-05),

2. 12533362 - Methods for treating diseases associated with ciliopathies (2026-01-27),

3. 12497445 - MONOVALENT ANTI-PROPERDIN ANTIBODIES AND ANTIBODY FRAGMENTS (2025-12-16),

4. 12460012 - Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients (2025-11-04),

5. 12459992 - Methods for treatment of refractory generalized myasthenia gravis (2025-11-04),

6. 12433938 - Alkaline phosphatase polypeptides and methods of use thereof (2025-10-07),

7. 12428484 - Anti-ALK2 antibodies and uses thereof (2025-09-30),

8. 12404320 - Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients (2025-09-02),

9. 12398387 - Compositions and methods for preparing factor Xa and derivatives (2025-08-26),

10. 12350269 - Cerdulatinib for the treatment of b-cell malignancies (2025-07-08),

11. 12312394 - Methods of producing anti-C5 antibodies (2025-05-27),

12. 12268733 - Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase (2025-04-08),

13. 12240893 - Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) (2025-03-04),

14. 12233088 - Bis-choline tetrathiomolybdate for treating Wilson Disease (2025-02-25),

15. 12221473 - Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof (2025-02-11),

Company Overview

Alexion Pharmaceuticals, Inc., headquartered in Boston, MA, specializes in the development of innovative antibody therapies aimed at treating rare and complex diseases. The company focuses on core technology areas such as anti-C5 antibodies and protein kinase inhibitors, addressing conditions like atypical hemolytic uremic syndrome and lysosomal storage diseases. With a commitment to advancing treatment options, Alexion is dedicated to improving patient outcomes through its research in complement disorders and related therapeutic fields.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

199 Patents

#18 in Boston, MA

#120 in Massachusetts

#2,073 in US

#4,244 in the World

Boston, MA, United States of America

Alexion Pharmaceuticals, Inc.

Forward Citations = 1,682

243 inventors:

Russell P Rother (36 out of 38 patents)

Katherine S Bowdish (27 out of 27 patents)

Douglas L Sheridan (25 out of 25 patents)

4. Paul P Tamburini (22 out of 29 patents)

5. Yi Wang (21 out of 21 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Alexion Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/alexion-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…